Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".
Saved in:
| Title: | Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial". |
|---|---|
| Authors: | Yim SY; Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea., Lee SH; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea., Kim JH; Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea., Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee JS; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Clinical and molecular hepatology [Clin Mol Hepatol] 2025 Jan; Vol. 31 (1), pp. e84-e86. Date of Electronic Publication: 2024 Oct 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Korean Association for the Study of the Liver Country of Publication: Korea (South) NLM ID: 101586730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2287-285X (Electronic) Linking ISSN: 22872728 NLM ISO Abbreviation: Clin Mol Hepatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
| ISSN: | 2287-285X |
|---|---|
| DOI: | 10.3350/cmh.2024.0830 |
